Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Daily

Download Data

Relmada Therapeutics Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Relmada Therapeutics Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Relmada Therapeutics Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Relmada Therapeutics Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Relmada Therapeutics Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends